Hemangiomas of infancy: Clinical and biological characteristics

Clinical Pediatrics

Volumn 44, Issue 9, 2005, Pages 747-766

  Smolinski, Kara N ^a   Yan, Albert C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; COLLAGENASE; CORTICOSTEROID; CYCLINE; CYTOCHROME B; GLUCOSE TRANSPORTER 1; IMIQUIMOD; INTERLEUKIN 12; OXYHEMOGLOBIN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PREDNISOLONE; PREDNISONE; SOMATOMEDIN B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANEMIA; AORTA COARCTATION; ARTERY MALFORMATION; BACK; CEREBELLUM ATROPHY; CLINICAL EXAMINATION; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL HEART MALFORMATION; CORPUS CALLOSUM AGENESIS; CORTICOSTEROID THERAPY; DANDY WALKER SYNDROME; EYE MALFORMATION; FACE; FEVER; FOLLOW UP; GASTRITIS; GROWTH RETARDATION; HEMANGIOMA; HEMANGIOMATOSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INFANT DISEASE; INFECTION; IRRITABILITY; KASABACH MERRITT SYNDROME; MYALGIA; NEUTROPENIA; ORBIT; PELVIS; PERINEUM; PHACES SYNDROME; POSTERIOR FOSSA; PULSED DYE LASER; REVIEW; SCLEROTHERAPY; SIDE EFFECT; SKIN HEMANGIOMA; SPASTICITY; STERNUM; SYNDROME; ULCER; VASCULAR ENDOTHELIUM; WEIGHT GAIN; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; FEMALE; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; MALE;

EID: 28844500335     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280504400902     Document Type: Review

References (144)

1. Holmahl K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 1955;44:370-379.
2. Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. 1957;86 (1):8-10.
3. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. 1976;58(2):218-222.
4. Pratt AG. Birthmarks in infants. AMA Arch Derm Syphilol. 1953;67(3):302-305.
5. Amir J, Metzker A, Krikler R, et al. Strawberry hemangioma in preterm infants. Pediatr Dermatol. 1986;3 (4):331-332.
6. Powell TG, West CR, Pharoah PO, et al. Epidemiology of strawberry haemangioma in low birthweight infants. Br J Dermatol. 1987;116(5):635-641.
7. Blei F, Walter J, Orlow SJ, et al. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol. 1998;134(6):718-722.
8. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol. 1997;13:375-423.
9. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412-422.
10. Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983;18(6):894-900.
11. Bowers R, Graham E, Tomlinson K. The natural history of the strawberry nevus. Arch Dermatol. 1960;82:667-680.
12. Lister W. The natural history of strawberry nevi. Lancet. 1938;1:1429-1434.
13. Waner M, Suen J. Hemangiomas and vascular malfomations of the head and neck. In: M Waner JS, ed. The Natural History of Hemangiomas. New York: Wiley-Liss; 1999:13-46.
14. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg. 2000;37(8):517-584.
15. Goldberg NS, Rosanova MA. Periorbital hemangiomas. Dermatol Clin. 1992;10(4):653-661.
16. Haik BG, Karcioglu ZA, Gordon RA, et al. Capillary hemangioma (infantile periocular hemangioma). Surv Ophthalmol. 1994;38(5):399-426.
17. Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol. 2004;21(1):1-9.
18. Bouchard S, Yazbeck S, Lallier M. Perineal hemangioma, anorectal malformation, and genital anomaly: a new association? J Pediatr Surg. 1999;34(7):1133-1135.
19. Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics. 1989;83(6):977-980.
20. Allen RM, Sandquist MA, Piatt JH Jr, et al. Ultrasonographic screening in infants with isolated spinal strawberry nevi. J Neurosurg. 2003;98(3 Suppl):247-250.
21. Humphreys RP. Clinical evaluation of cutaneous lesions of the back: spinal signatures that do not go away. Clin Neurosurg. 1996;43:175-187.
22. Serna MJ, Vazquez-Doval J, Vanaclocha V, et al. Occult spinal dysraphism: a neurosurgical problem with a dermatologic hallmark. Pediatr Dermatol. 1993;10(2):149-152.
23. Tubbs RS, Wellons JC, 3rd, Iskandar BJ, et al. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg. 2004;100(2 Suppl):86-89.
24. Waner M, North PE, Scherer KA, et al The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003;139(7):869-875.
25. Metry DW, Hawrot A, Altman C, et al. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol. 2004;140(5):591-596.
26. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr. 1997;131(4):643-646.
27. Sie KC, Tampakopoulou DA. Hemangiomas and vascular malformations of the airway. Otolaryngol Clin North Am. 2000;33(1):209-220.
28. Azizkhan RG. Laser surgery: new applications for pediatric skin and airway lesions. Curr Opin Pediatr. 2003;15(3):243-247.
29. Madgy D, Ahsan SF, Rest D, et al. The application of the potassium-titanyl-phosphate (KTP) laser in the management of subglottic hemangioma. Arch Otolaryngol Head Neck Surg. 2001;127(1):47-50.
30. Froehlich P, Seid AB, Morgon A. Contrasting strategic approaches to the management of subglottic hemangiomas. Int J Pediatr Otorhinolaryngol. 1996;36(2):137-146.
31. Hughes CA, Rezaee A, Ludemann JP, et al. Management of congenital subglottic hemangioma. J Otolaryngol. 1999;28(4):223-228.
32. Hawkins DB, Crockett DM, Kahlstrom EJ, et al. Corticosteroid management of airway hemangiomas: long-term follow-up. Laryngoscope. 1984;94(5 Pt 1):633-637.
33. Brook I. Microbiology of infected hemangiomas in children. Pediatr Dermatol. 2004;21(2):113-116.
34. Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol. 2001;44(6):962-972.
35. Metz BJ, Rubenstein MC, Levy ML, et al. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol. 2004;140(7):867-870.
36. David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg. 2003;56(4):317-327.
37. Morelli JG, Tan OT, Weston WL. Treatment of ulcerated hemangiomas with the pulsed tunable dye laser. Am J Dis Child. 1991;145(9):1062-1064.
38. Morelli JG, Tan OT, Yohn JJ, et al. Treatment of ulcerated hemangiomas infancy. Arch Pediatr Adolesc Med. 1994;148(10):1104-1105.
39. Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132(3):307-311.
40. Metry DW, Dowd CF, Barkovich AJ, et al. The many faces of PHACE syndrome. J Pediatr. 2001;139(1):117-123.
41. Poetke M, Frommeld T, Berlien HP. PHACE syndrome: new views on diagnostic criteria. Eur J Pediatr Surg. 2002;12(6):366-374.
42. Bronzetti G, Giardini A, Patrizi A, et al. Ipsilateral hemangioma and aortic arch anomalies in posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta, and cardiac defects and eye abnormalities (PHACE) anomaly: report and review. Pediatrics. 2004;113(2):412-415.
43. Stern JK, Wolf JE Jr, Jarratt M. Benign neonatal hemangiomatosis. J Am Acad Dermatol. 1981;4(4):442-445.
44. Leung AK, Rafaat M. Benign neonatal hemangiomatosis. Pediatr Dermatol. 2003;20(2):161-163.
45. Baska EB, Baykara M, Saricaoglu H, et al. Benign neonatal hemangiomatosis with conjunctival involvement. Report of a case and review of the literature. Acta Derm Venereol. 2002;82(2):124-127.
46. Herszkowicz L, dos Santos RG, Alves EV, et al. Benign neonatal hemangiomatosis with mucosal involvement. Arch Dermatol. 2001;137(6):828-829.
47. Dyall-Smith D, Cowen P. Benign neonatal hemangiomatosis. Int J Dermatol. 1992;31(5):336-338.
48. Blei F, Orlow SJ, Geronemus R. Multimodal management of diffuse neonatal hemangiomatosis. J Am Acad Dermatol 1997;37(6):1019-1021.
49. Golitz LE, Rudikoff J, O'Meara OP. Diffuse neonatal hemangiomatosis. Pediatr Dermatol. 1986;3(2):145-152.
50. Holden KR, Alexander F. Diffuse neonatal hemangiomatosis. Pediatrics. 1970;46(3):411-421.
51. Stratte EG, Tope WD, Johnson CL, et al. Multimodal management of diffuse neonatal hemangiomatosis. J Am Acad Dermatol. 1996;34(2 Pt 2):337-342.
52. Geller JD, Topper SF, Hashimoto K. Diffuse neonatal hemangiomatosis: a new constellation of findings. J Am Acad Dermatol. 1991;24(5 Pt 2):816-818.
53. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185-189.
54. North PE, Waner M, James CA, et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol. 2001;137(12):1607-1620.
55. Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr. 1996;128(3):3 29-335.
56. Berenguer B, Mulliken JB, Enjolras O, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol. 2003.
57. Konez O, Burrows PE, Mulliken JB, et al. Angiographic features of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol. 2003;33(1):15-19.
58. Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg. 2001;107(7):1647-1654.
59. Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol. 2004;50(6):875-882.
60. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr. 1997;130(4):631-640.
61. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol. 2001;112(4):851-862.
62. Maguiness S, Guenther L. Kasabach-merritt syndrome. J Cutan Med Surg. 2002;6(4):335-339.
63. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100(6):1377-1386.
64. Vin-Christian K, McCalmont TH, Frieden IJ. Kaposiform hemangioendothelioma. An aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy. Arch Dermatol. 1997;133(12):1573-1578.
65. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg. 2001;27(5):475-485.
66. Morelli JG. Use of lasers in pediatric dermatology. Dermatol Clin. 1998;16(3):489-495.
67. Margileth AM, Museles M. Cutaneous hemangiomas in children. Diagnosis and conservative management. JAMA. 1965;194(5):523-526.
68. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39 (1):76-83.
69. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72(3):351-357.
70. Bennett ML, Fleischer AB Jr, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213.
71. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus. 1994;31(3):153-156.
72. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology. 1995;102 (12):2012-2015.
73. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg. 2000;35(3):420-423.
74. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-969.
75. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-1623.
76. Rampini E, Rampini P, Occella C, et al. Interferon alpha 2b for treatment of complex cutaneous haemangiomas of infancy: a reduced dosage schedule. Br J Dermatol. 2000;142 (1):189-191.
77. Bauman NM, Burke DK, Smith RJ. Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon. Otolaryngol Head Neck Surg. 1997;117(1):99-110.
78. Blei F, Orlow SJ, Geronemus RG. Interferon alfa-2a therapy for extensive perianal and lower extremity hemangioma. J Am Acad Dermatol. 1993;29(1):98-99.
79. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol. 1997;19(3):237-244.
80. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326 (22):1456-1463.
81. Garmendia G, Miranda N, Borroso S, et al. Regression of infancy hemangiomas with recombinant IFN-alpha 2b. J Interferon Cytokine Res. 2001;21(1):31-38.
82. MacArthur CJ, Senders CW, Katz J. The use of interferon alfa-2a for life-threatening hemangiomas. Arch Otolaryngol Head Neck Surg. 1995;121(6):690-693.
83. Ricketts RR, Hatley RM, Corden BJ, et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg. 1994;219(6):605-612; discussion 612-614.
84. White CW, Wolf SJ, Korones DN, et al. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991;118(1):59-66.
85. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999;135(6):782-785.
86. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 Pt 1):527-530.
87. Ashinoff R, Geronemus RG. Capillary hemangiomas and treatment with the flash lamp-pumped pulsed dye laser. Arch Dermatol. 1991;127 (2):202-205.
88. Ashinoff R, Geronemus RG. Failure of the flashlamp-pumped pulsed dye laser to prevent progression to deep hemangioma. Pediatr Dermatol. 1993;10(1):77-80.
89. Barlow RJ, Walker NP, Markey AC. Treatment of proliferative haemangiomas with the 585 nm pulsed dye laser. Br J Dermatol. 1996;134(4):700-704.
90. Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360(9332):521-527.
91. Garden JM, Bakus AD, Paller AS. Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: prospective analysis. J Pediatr. 1992;120(4 Pt 1):555-560.
92. Geronemus RG, Kauvar AN. The pulsed-dye laser for infantile hemangiomas. Plast Reconstr Surg. 1996;97(6):1302-1303.
93. Michel JL. Treatment of hemangiomas with 595 nm pulsed dye laser dermobeam. Eur J Dermatol. 2003;13(2):136-141.
94. Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas. Arch Dermatol. 2000;136(5):628-632.
95. Scheepers JH, Quaba AA. Does the pulsed tunable dye laser have a role in the management of infantile hemangiomas? Observations based on 3 years' experience. Plast Reconstr Surg. 1995;95(2):305-312.
96. Tang P, Hornicek FJ, Gebhardt MC, et al. Surgical treatment of hemangiomas of soft tissue. Clin Orthop. 2002(399):205-210.
97. Aldave AJ, Shields CL, Shields JA. Surgical excision of selected amblyogenic periorbital capillary hemangiomas. Ophthalmic Surg Lasers. 1999;30(9):754-757.
98. Plager DA, Snyder SK. Resolution of astigmatism after surgical resection of capillary hemangiomas in infants. Ophthalmology. 1997;104(7):1102-1106.
99. Walker RS, Custer PL, Nerad JA. Surgical excision of periorbital capillary hemangiomas. Ophthalmology. 1994;101(8):1333-1340.
100. Deans RM, Harris GJ, Kivlin JD. Surgical dissection of capillary hemangiomas. An alternative to intralesional corticosteroids. Arch Ophthalmol. 1992;110(12):1743-1747.
101. Apfelberg DB. Argon and YAG laser photocoagulation and excision of hemangiomas and vascular malformations of the nose. West J Med. 1995;163(2):122-127.
102. McCarthy JG, Borud LJ, Schreiber JS. Hemangiomas of the nasal tip. Plast Reconstr Surg. 2002;109(1):31-40.
103. Warren SM, Longaker MT, Zide BM. The subunit approach to nasal tip hemangiomas. Plast Reconstr Surg. 2002;109(1):25-30.
104. van der Meulen JC, Gilbert M, Roddi R. Early excision of nasal hemangiomas: the L-approach. Plast Reconstr Surg. 1994;94(3):465-473; discussion 474-475.
105. Denk MJ, Ajkay N, Yuan X, et al. Surgical treatment of nasal hemangiomas. Ann Plast Surg. 2002;48(5):489-494; discussion 494-495.
106. Pitanguy I, Machado BH, Radwanski HN, et al. Surgical treatment of hemangiomas of the nose. Ann Plast Surg. 1996;36(6):586-592; discussion 592-593.
107. Matsumoto K, Nakanishi H, Koizumi Y, et al. Sclerotherapy of hemangioma with late involution. Dermatol Surg. 2003;29(6):668-671; discussion 671.
108. O'Donovan JC, Donaldson JS, Morello FP, et al. Symptomatic hemangiomas and venous malformations in infants, children, and young adults: treatment with percutaneous injection of sodium tetradecyl sulfate. Am J Roentgenol. 1997;169(3):723-729.
109. Kane WJ, Morris S, Jackson IT, et al. Significant hemangiomas and vascular malformations of the head and neck: clinical management and treatment outcomes. Ann Plast Surg. 1995;35(2):133-143.
110. Stefanova P, Chatalbashev N, Anastasov V. On combination treatment of hemangiomas in childhood. Folia Med (Plovdiv). 1994;36(3):41-47.
111. Hellmann JR, Myer CM 3rd, Prenger EC. Therapeutic alternatives in the treatment of life-threatening vasoformative tumors. Am J Otolaryngol. 1992;13(1):48-53.
112. Hayashi N, Masumoto T, Okubo T, et al. Hemangiomas in the face and extremities: MR-guided sclerotherapy-optimization with monitoring of signal intensity changes in vivo. Radiology. 2003;226(2):567-572.
113. Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol. 2002;138(7):881-884; discussion 884.
114. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139(10):1347-1350.
115. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003;121(5):1205- 1209.
116. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-570.
117. Wilson-Jones. Vascular Tumors: Tumors and Tumor-Like Conditions of Bloodvessels and Lymphatics. In: Elder D ER, Jaworsky C, Johnson Jr B, eds. Lever's Histopathology of the Skin. 8th ed. Philadelphia: Raven Publishers; 1997:889-932.
118. Tan ST, Velickovic M, Ruger BM, et al. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg. 2000;106(3):529-538.
119. Gonzalez-Crussi F, Reyes-Mugica M. Cellular hemangiomas ("hemangioendotheliomas") in infants. Light microscopic, immunohistochemical, and ultrastructural observations. Am J Surg Pathol. 1991;15(8):769-778.
120. Tan ST, Wallis RA, He Y, Davis PF. Mast cells and hemangioma. Plast Reconstr Surg. 2004;113(3):999-1011.
121. Hasan Q, Ruger BM, Tan ST, et al. Clusterin/apoJ expression during the development of hemangioma. Hum Pathol. 2000;31(6):691-697.
122. Frischer JS, Huang J, Serur A, et al. Biomolecular markers and involution of hemangiomas. J Pediatr Surg. 2004;39(3):400-404.
123. Razon MJ, Kraling BM, Mulliken JB, et al. Increased apoptosis coincides with onset of involution in infantile hemangioma. Micro circulation. 1998;5(2-3):189-195.
124. Nguyen VA, Furhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol. 2004;35(6):739-744.
125. North PE, Waner M, Brodsky MC. Are infantile hemangioma of placental origin? Ophthalmology. 2002;109 (2):223-224.
126. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest. 2001;107(6):745-752.
127. Walter JW, Blei F, Anderson JL, et al. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet. 1999;82(1):77-83.
128. Berg JN, Walter JW, Thisanagayam U, et al. Evidence for loss of heterozygosity of 5q in sporadic haemangiomas: are somatic mutations involved in haemangioma formation? J Clin Pathol. 2001;54(3):249-252.
129. Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002;33(3):295-303.
130. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood. 2004;103(4):1373-1375.
131. Dosanjh A, Chang J, Bresnick S, et al. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol. 2000;27(9):441-450.
132. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000;19(53):6122-6129.
133. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277(5322):48-50.
134. Yu Y, Varughese J, Brown LF, et al. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol. 2001;159(6):2271-2280.
135. Hasan Q, Tan ST, Gush J, et al. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105(1 Pt 1):117-120.
136. Hasan Q, Tan ST, Xu B, et al. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol Physiol. 2003;30(3):140-144.
137. Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg. 1999;103(1):1-9; discussion 10.
138. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6):2357-2364.
139. Kraling BM, Razon MJ, Boon LM, et al. F-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol. 1996;148 (4):1181-1191.
140. Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002;99(11):7455-7460.
141. Hasan Q, Tan ST, Gush J, et al. Altered mitochondrial cytochrome b gene expression during the regression of hemangioma. Plast Reconstr Surg. 2001;108(6):1471-1476; discussion 1477-1478.
142. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11-22.
143. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol. 2004;28(5):559-568.
144. Li Q, Yu Y, Bischoff J, et al. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J Pathol. 2003;201 (2):296-302.